Celyad price target lowered to $51 from $74 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff lowered his price target for Celyad to $51 after rolling forward his discount period to 2019. The analyst, however, keeps an Overweight rating on the shares after the company updated solid tumor data from the Think and Shrink studies of CYAD-01. Celyad will report Think data on 12 relapsed/refractory acute myeloid leukemia patients in December, Tenthoff tells investors in a research note. He also believes the company has enough cash to fund its operations through mid-2020.